Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novel Negative Pressure Wound Therapy System Cleared By FDA

Executive Summary

The FDA granted 510(k) clearance to Applied Tissue Technologies for its non-foam negative pressure wound therapy system. 

You may also be interested in...



Former Oracle Exec Joins FDA As Director Of Digital Health Center Of Excellence

Former Oracle cloud expert Troy Tazbaz brings cloud computing expertise to his new role as director of the Food and Drug Administration’s Digital Health Center of Excellence (DHCOE).

Reducing Antimicrobial Resistance With Rapid Tests

Widespread implementation of rapid diagnostic tests is critical for decreasing antimicrobial resistance. 

Easier Access To Funding: FCC Rural Health Care Program Seeks Comments On New Actions

The Federal Communications Commission recently approved four proposals and seeks comments on four others to increase telemedicine access for rural communities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel